7e68ed4c8b7981adb8f307943b5d27c6 7e68ed4c8b7981adb8f307943b5d27c6

“I am only one,

But still I am one.

I cannot do everything,

But still I can do something;

And because I cannot do everything,

I will not refuse to do the something that I can do.”



Please read Stella's story as an example of how SKC's fundraising can help save lives.








Stella's story is also an example of how dinutuximab antibody therapy is a much needed therapy approved by the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe and is now the standard treatment for children with high-risk neuroblastoma in many countries.


However the UK's National Institute for Health and Care Excellence (NICE) have denied access to the therapy on the NHS.


"NICE based their decision on an annual cost to the NHS projected at just over £2m to give these children a greater chance of survival and a full and normal life.


In future, UK children diagnosed with high-risk neuroblastoma will need to join a clinical trial to benefit from antibody therapy, which is frankly unethical when an effective drug has been approved. The only alternative will be for parents to raise in excess of £500,000, as well as enormous reserves of emotional resilience and determination, to take their sick child abroad for the greater chance of survival dinutuximab therapy provides."

Steve Richards, CEO of Solving Kids’ Cancer


You can help fight this decision.  This link will give you the details and tell you how you can help:

Stella's Story SKC Solving Kids Cancer - Letter of Authority with add